🔍

ALBERTDAVD - Albert David

📊 NSE: ALBERTDAVD 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/13/2025 18:07

📢 Recent Corporate Announcements

Albert David Ltd International Business Leader Resigns Effective March 27, 2026

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 10 Mar 2026, 05:20 PM

Albert David Limited has announced the resignation of Mr. Thakkar Rushabh Kishorbhai, who served as the International Business Leader. The resignation was officially communicated on March 10, 2026, and his tenure will conclude on March 27, 2026. The departure is attributed to the individual seeking better career opportunities elsewhere. The company has expressed appreciation for his contributions during his time with the organization.

Mr. Thakkar Rushabh Kishorbhai has resigned from the position of International Business Leader.
The resignation is effective from the close of business hours on March 27, 2026.
The stated reason for the cessation is the pursuit of a better job opportunity.
The company filed the intimation under Regulation 30 of the SEBI LODR Regulations.

💡 Investors should monitor for the appointment of a successor to ensure there is no disruption in the company's international business strategy. No immediate portfolio changes are recommended based on this routine management exit.

Albert David Q3 Results: Net Profit at ₹15.30 Cr vs Loss of ₹9.39 Cr YoY; Revenue Up 8%

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 11 Feb 2026, 05:08 PM

Albert David Limited reported a significant turnaround in Q3 FY26, posting a net profit of ₹15.30 crore compared to a net loss of ₹9.39 crore in the same period last year. Revenue from operations grew 8.2% YoY to ₹89.93 crore, while sequential growth was also positive. The bottom line was heavily supported by a sharp rise in 'Other Income' which reached ₹12.40 crore. However, on a nine-month basis, the net profit of ₹19.94 crore still lags behind the ₹27.53 crore recorded in the previous year.

Revenue from operations increased 8.2% YoY to ₹8,992.69 Lakhs from ₹8,308.29 Lakhs.
Net Profit turned positive at ₹1,530.38 Lakhs against a loss of ₹938.78 Lakhs in Q3 FY25.
Other Income spiked to ₹1,239.93 Lakhs compared to a negative ₹900.67 Lakhs in the year-ago period.
Earnings Per Share (EPS) recovered to ₹26.81 from a negative ₹16.45 YoY.
Total expenses for the quarter were lower at ₹8,242.37 Lakhs compared to ₹8,423.69 Lakhs YoY.

💡 Investors should view the return to profitability positively, but must scrutinize the high 'Other Income' component to determine if it is a one-time gain or sustainable. The stock remains a watch to see if operational revenue growth can continue to offset the nine-month performance lag.

Albert David Q3 FY26 Results: Net Profit Swings to ₹15.3 Cr from Loss YoY

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 11 Feb 2026, 04:47 PM

Albert David Limited reported a significant turnaround in Q3 FY26, posting a net profit of ₹15.30 crore compared to a net loss of ₹9.39 crore in the same quarter last year. Revenue from operations grew by 8.2% year-on-year to ₹89.93 crore, while total income saw a sharper rise to ₹102.33 crore, aided by a substantial increase in other income. The company's earnings per share (EPS) improved to ₹26.81 from a negative ₹16.45 in the year-ago period. However, for the nine-month period ended December 2025, the net profit of ₹19.94 crore remains lower than the ₹27.53 crore recorded in the corresponding period of the previous year.

Net Profit of ₹15.30 crore in Q3 FY26 vs a Net Loss of ₹9.39 crore in Q3 FY25.
Revenue from operations increased to ₹89.93 crore from ₹83.08 crore YoY.
Other income surged to ₹12.40 crore, significantly boosting the bottom line compared to negative other income in previous quarters.
9M FY26 profit stands at ₹19.94 crore, down 27.6% compared to ₹27.53 crore in 9M FY25.
Quarterly EPS recovered to ₹26.81 from a loss of ₹16.45 in the previous year's December quarter.

💡 Investors should monitor if the recovery in profitability is sustainable or driven primarily by the surge in 'Other Income'. The turnaround from a loss-making position is a positive signal, but the year-to-date decline in profit suggests overall growth remains under pressure.

Albert David Reports Resignation of EA to MD & CEO Snehal Tushar Bhosale

🟡 NEUTRAL ⭐ 3/10

MANAGEMENT 📅 17 Jan 2026, 01:44 PM

Albert David Limited has announced the resignation of Mrs. Snehal Tushar Bhosale, who served as the Executive Assistant (EA) to the Managing Director & CEO. The resignation was effective as of the close of business hours on January 16, 2026. The company stated that the departure was due to personal reasons. This disclosure is a regulatory requirement under SEBI LODR Regulations for changes in Senior Management Personnel.

Mrs. Snehal Tushar Bhosale resigned from her role as Executive Assistant to the MD & CEO.
The resignation became effective at the close of business on January 16, 2026.
The departure was cited as being for personal reasons.
The announcement was made in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.

💡 This is a routine management update regarding a support role and is unlikely to impact the company's financial performance or strategic direction. No immediate action is required from investors.

Albert David Submits SEBI Regulation 74(5) Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 05 Jan 2026, 04:33 PM

Albert David Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The filing covers the period from October 1, 2025, to December 31, 2025. The certificate, issued by Maheshwari Datamatics Pvt. Ltd., confirms that physical security certificates received for dematerialization were processed and cancelled. This is a standard administrative procedure to ensure the transition from physical to electronic shareholding is handled correctly.

Compliance certificate for the quarter ended December 31, 2025.
Issued by Registrar and Share Transfer Agent, Maheshwari Datamatics Pvt. Ltd.
Confirms that security certificates were mutilated and cancelled after dematerialization.
Verification that the name of depositories has been substituted in the company's records.
Submitted to both National Securities Depository Ltd (NSDL) and Central Depository Services (India) Ltd (CDSL).

💡 No action is required from investors as this is a routine regulatory filing confirming standard administrative compliance.

Albert David to Close Trading Window from Jan 1, 2026, for Q3 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 22 Dec 2025, 03:11 PM

Albert David Limited has announced the closure of its trading window starting January 1, 2026, in compliance with SEBI Insider Trading regulations. This closure is a standard procedure ahead of the declaration of the unaudited financial results for the third quarter and nine-month period ending December 31, 2025. The window will remain closed for all designated persons and their immediate relatives until 48 hours after the results are officially announced. The company will also implement PAN freezing for designated persons through CDSL to ensure regulatory compliance.

Trading window closure begins on Wednesday, January 1, 2026.
Closure is related to the financial results for the quarter and nine months ending December 31, 2025.
Trading restriction applies to all designated persons and their immediate relatives.
The window will reopen 48 hours after the board meeting for financial results concludes.
Company will freeze PANs of designated persons at the ISIN level (INE155C01010) via CDSL.

💡 This is a routine regulatory announcement and does not impact the company's fundamentals. Investors should monitor for the upcoming board meeting date to review the Q3 financial performance.

Albert David Limited to Close Trading Window from Jan 1, 2026 for Q3 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 22 Dec 2025, 01:40 PM

Albert David Limited has announced the closure of its trading window starting January 1, 2026, in compliance with SEBI Prohibition of Insider Trading Regulations. This closure is ahead of the declaration of unaudited financial results for the third quarter and nine-month period ending December 31, 2025. The restriction applies to all designated persons and their immediate relatives, with PAN freezing implemented via CDSL. The window will reopen 48 hours after the financial results are officially declared to the exchanges.

Trading window closure effective from Wednesday, January 1, 2026.
Closure pertains to the unaudited financial results for the quarter and nine months ending December 31, 2025.
PAN freezing for designated persons will be executed through CDSL as per SEBI circulars.
Trading window will reopen 48 hours after the board meeting results are announced.

💡 This is a routine regulatory announcement and does not require any immediate action from retail investors. Investors should monitor for the upcoming board meeting date to evaluate the company's Q3 financial performance.

Albert David MD & CEO Umesh Manohar Kunte Resigns Effective December 18, 2025

🔵 WATCH ⭐ 7/10

MANAGEMENT 📅 18 Dec 2025, 07:39 PM

Albert David Limited has announced the resignation of Mr. Umesh Manohar Kunte from his positions as Managing Director, Chief Executive Officer, and Director. The resignation is effective from the close of business hours on December 18, 2025, citing personal reasons and priorities. Consequently, Mr. Kunte also ceases to be a Key Managerial Person (KMP) of the company. The Board of Directors accepted the resignation during a meeting that concluded at 19:20 HRS on the same day.

Mr. Umesh Manohar Kunte (DIN: 03398438) resigns as MD, CEO, and Director effective Dec 18, 2025.
The resignation is attributed to personal reasons and priorities of the outgoing executive.
Mr. Kunte will no longer serve as a Key Managerial Person (KMP) under Section 203 of the Companies Act.
The Board meeting approving the transition took place on December 18, 2025, from 17:00 to 19:20 HRS.

💡 Investors should monitor the company's next steps regarding the appointment of a new CEO/MD to ensure leadership continuity. Any delay in finding a replacement or a shift in strategic direction should be watched closely.

Albert David MD & CEO Umesh Manohar Kunte Resigns Effective Dec 18, 2025

🔵 WATCH ⭐ 7/10

MANAGEMENT 📅 18 Dec 2025, 07:33 PM

Albert David Limited has announced the resignation of Mr. Umesh Manohar Kunte from his roles as Managing Director, CEO, and Director. The resignation is effective from the close of business on December 18, 2025, citing personal reasons and priorities. As a result, Mr. Kunte also ceases to be a Key Managerial Person (KMP) for the company. The board accepted the resignation in a meeting concluded at 19:20 HRS on the same day, and a successor has not yet been named.

Resignation of Mr. Umesh Manohar Kunte as MD, CEO, and Director effective Dec 18, 2025
Departure is attributed to personal reasons and priorities of the outgoing executive
The Board of Directors meeting for this decision lasted from 17:00 to 19:20 HRS
Mr. Kunte ceases to be a Key Managerial Person (KMP) under Section 203 of the Companies Act

💡 Investors should monitor for the appointment of a new CEO to assess the future strategic direction and leadership stability. Maintain a cautious stance until a clear transition plan is announced by the board.

Albert David MD & CEO Umesh Manohar Kunte Resigns Effective December 18, 2025

🔵 WATCH ⭐ 7/10

MANAGEMENT 📅 18 Dec 2025, 07:30 PM

Albert David Limited has announced the resignation of Mr. Umesh Manohar Kunte from his positions as Managing Director, CEO, and Director. The resignation is effective from the closure of business hours on December 18, 2025, following a Board meeting held on the same day. Mr. Kunte cited personal reasons and priorities for his departure from the company. Consequently, he also ceases to be a Key Managerial Person (KMP) under the Companies Act, 2013.

Mr. Umesh Manohar Kunte resigned as Managing Director, CEO, and Director effective December 18, 2025.
The resignation was accepted by the Board in a meeting that concluded at 19:20 HRS IST.
The departure is attributed to personal reasons and priorities of the outgoing executive.
Mr. Kunte will no longer serve as a Key Managerial Person (KMP) for determining materiality of events.
The company has placed on record its appreciation for his contributions during his tenure.

💡 Investors should monitor the company's upcoming announcements regarding the appointment of a new MD and CEO to ensure leadership stability. Sudden changes in top management can lead to short-term stock volatility.

View All ALBERTDAVD Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The company operates in a single pharmaceutical segment. Total revenue from operations for FY25 was INR 345.76 Cr, representing a decline of 4.61% compared to INR 362.46 Cr in FY24.

Geographic Revenue Split

Not disclosed in available documents as the company operates in a single segment and does not segregate by geographical presence.

Profitability Margins

Profitability saw a significant decline in FY25. Operating Profit Margin turned negative at -3.61% from 4.95% in FY24. Net Profit Margin dropped to 5.01% from 20.93% YoY. Return on Net Worth decreased by 18.86 percentage points to 6.27% from 25.13%.

EBITDA Margin

EBITDA margin for FY25 was 9.43% (INR 32.61 Cr), a sharp decline of 68.77% from INR 104.43 Cr (28.81% margin) in FY24 due to increased employee and distribution expenses.

Capital Expenditure

Historical capital expenditure for the half-year ended September 30, 2025, was INR 6.28 Cr, primarily for upgrading facilities as per Revised Schedule-M.

Credit Rating & Borrowing

CARE A; Negative (Outlook revised from Stable in June 2025). Borrowings increased to INR 39.52 Cr as of September 2025 from INR 10.05 Cr in March 2025, leading to a 366.97% increase in the Debt-Equity ratio to 0.03.

⚙️ Operational Drivers

Capacity Expansion

The company is currently upgrading its manufacturing units to comply with Revised Schedule-M standards to meet market demand and improve cost control.

Manufacturing Efficiency

Efforts are being made to adopt the latest technology to upgrade units for effective cost control; however, specific utilization percentages were not disclosed.

Logistics & Distribution

Sales and distribution costs increased significantly in FY25 as part of a strategy to expand market reach and product penetration.

📈 Strategic Growth

Expected Growth Rate

9.80%

Growth Strategy

Growth is targeted through upgrading facilities to Revised Schedule-M standards, R&D focus on new molecules and drug delivery systems, and increased spending on sales and distribution to penetrate new markets.

Products & Services

Placenta-based drugs and other pharmaceutical formulations.

Brand Portfolio

Albert David.

New Products/Services

R&D team is working on new molecules to strengthen the product pipeline; expected revenue contribution was not disclosed.

Market Expansion

The company is expanding its market reach through higher sales and distribution costs, though specific target regions were not named.

Market Share & Ranking

The company holds an established market position in placenta-based drugs.

🌍 External Factors

Industry Trends

The pharmaceutical industry is highly challenging with a focus on quality and drug delivery systems. The industry is evolving towards stricter manufacturing standards like Revised Schedule-M.

Competitive Landscape

The company operates in a highly challenging pharmaceutical market with moderate scale of operations compared to larger peers.

Competitive Moat

The moat is built on an established market position in placenta-based drugs and a strong distribution network, which are sustainable due to the specialized nature of these products.